The link between CaSR and EMT in breast cancer is yet to be explored, but studies have shown that inducing CaSR in colon cancer (where it acts as a tumor-suppressor) inhibits EMT and lower expression in lung adenocarcinomas promotes a mesenchymal phenotype (84–86). Here, CASR is linked to lung adenocarcinoma.